Influvac Special Precautions

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine. Influvac 2025 should under no circumstances be administered intravascularly.
As with other vaccines administered intramuscularly, Influvac should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects. Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions can occur following, or even before, any vaccination as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints. Influvac is not effective against all possible strains of influenza virus. Influvac is intended to provide protection against those strains of virus from which the vaccine is prepared and to closely related strains. As with any vaccine, a protective immune response may not be elicited in all vaccines. Antibody response in patients with endogenous or iatrogenic immunosuppression maybe insufficient.
Interference with serological testing: see Interactions. This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e essentially 'sodium-free'. This medicine contains potassium, less than 1 mmol (39 mg) per dose, i.e essentially "potassium-free".
Effects on ability to drive and use machines: Influvac 2025 has no or negligible influence on the ability to drive and use machines.